Author |
Topic: Triptans: Peter Goadsby on mode of action (Read 1992 times) |
|
Bob_Johnson
New Board Hall of Famer
Gender: 
Posts: 1796
|
 |
Triptans: Peter Goadsby on mode of action
« on: Nov 13th, 2006, 8:17am » |
 Quote  Modify
|
Interesting to note that he is saying that the primary mode of action is NOT as a vasoconstrictor but on its effect on the central nervous system. Doesn't change our appreciation of this class of meds but suggests we need to change how we think about the nature of CH.
==============================
Handb Exp Pharmacol. 2007;(177):129-43.
Serotonin receptor ligands: treatments of acute migraine and cluster headache.
Goadsby PJ.
Institute of Neurology, Queen Square, London WC1N 3BG, UK. peterg@ion.ucl.ac.uk
Fuelled by the development of the serotonin 5-HT(1B/1D) receptor agonists, the triptans, the last 15 years has seen an explosion of interest in the treatment of acute migraine and cluster headache. Sumatriptan was the first of these agonists, and it launched a wave of therapeutic advances. These medicines are effective and safe. Triptans were developed as cranial vasoconstrictors to mimic the desirable effects of serotonin, while avoiding its side-effects. It has subsequently been shown that the triptans' major action is neuronal, with both peripheral and central trigeminal inhibitory effects, as well as actions in the thalamus and at central modulatory sites, such as the periaqueductal grey matter. Further refinements may be possible as the 5-HT(1D) and 5-HT(1F) receptor agonists are explored. Serotonin receptor pharmacology has contributed much to the better management of patients with primary headache disorders.
PMID: 17087122 [PubMed]
|
| « Last Edit: Nov 14th, 2006, 7:17am by Bob_Johnson » |
 IP Logged |
Bob Johnson
|
|
|
MJ
New Board Hall of Famer
Gender:
Posts: 911
|
|
Re: Triptans: Peter Goadsby on mode of action
« Reply #1 on: Nov 13th, 2006, 12:29pm » |
Quote Modify
|
on Nov 13th, 2006, 8:17am, Bob_Johnson wrote:Interesting to note that he is saying that the primary mode of action is NOT as a vasoconstrictor but on it effect on the central nervous system. Doesn't change our appreciation of this class of meds but suggests we need to change how we think about the nature of CH.
|
|
Bob I find your statement interesting.
I have often wondered since Oxygen has an opposite effect on me (more pain) from what most people report as a vasoconstrictive remedy, if this doesnt somehow trigger a serotonin response trigger as well. With me it may just be triggering an incorrect receptor response as there is a multitude of differing receptors..
To date I have not seen anything to support or denounce this
Just a thought.
Some additional reading on understanding serotonin and triptans.
http://www.clusterbusters.com/Scientific.htm
|
|
IP Logged |
MJ
|
|
|
Kevin_M
CH.com Alumnus
New Board Hall of Famer
withered branches grow green again.
Gender:
Posts: 6184
|
|
Re: Triptans: Peter Goadsby on mode of action
« Reply #2 on: Nov 13th, 2006, 7:58pm » |
Quote Modify
|
on Nov 13th, 2006, 8:17am, Bob_Johnson wrote:==============================
Handb Exp Pharmacol. 2007;(177):129-43.
Serotonin receptor ligands: treatments of acute migraine and cluster headache.
Goadsby PJ.
Institute of Neurology, Queen Square, London WC1N 3BG, UK. peterg@ion.ucl.ac.uk
Fuelled by the development of the serotonin 5-HT(1B/1D) receptor agonists, the triptans, the last 15 years has seen an explosion of interest in the treatment of acute migraine and cluster headache.
-----/ /-----
It has subsequently been shown that the triptans' major action is neuronal, with both peripheral and central trigeminal inhibitory effects, as well as actions in the thalamus and at central modulatory sites, such as the periaqueductal grey matter
-----/ /------
Further refinements may be possible as the 5-HT(1D) and 5-HT(1F) receptor agonists are explored.
PMID: 17087122 [PubMed]
|
|
Gears still churning.
Thanks again Bob. 
|
|
IP Logged |
|
|
|
|
|
|
Home
Help
Search
Members
Member Map
Login
Register
Reply
Notify of replies
Send Topic
Print
test rss